Summary of COVID-19 artemisinin studies

1. Lin et al., Clinical study of artesunate in the treatment of coronavirus disease 2019

43 patient artemisinin late treatment study: 31% faster recovery (p=0.02), 8% shorter hospitalization (p=0.22), and 29% faster viral clearance (p=0.05).
Prospective study of 43 hospitalized COVID-19 patients in China showing faster symptom improvement and shorter hospitalization with artesunate. Artesunate 60 mg twice daily for 10 days.
Apr 2020, China Critical Care Medicine, https://rs.yiigle.com/cmaid/1203190, https://c19p.org/lin7

2. Trieu et al., Targeting TGF-β pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19

60 patient artemisinin early treatment RCT: 52% improved recovery (p=0.08).
RCT 60 mild-moderate COVID-19 patients showing faster recovery with artemisinin.
Jan 2021, medRxiv, https://www.medrxiv.org/content/10.1101/2021.01.24.21250418, https://c19p.org/trieu

3. Chandiwana et al., Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

114 patient artemisinin early treatment RCT: 29% lower progression (p=0.66), 27% faster recovery (p=0.1), and 1% worse viral clearance (p=0.76).
Very high COI low-risk patient RCT in South Africa, showing no significant differences with artesunate-amodiaquine or pyronaridine-artesunate.
Oct 2022, eBioMedicine, https://www.sciencedirect.com/science/article/pii/S2352396422005047, https://c19p.org/chandiwanaart